Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease

Fineline Cube Apr 15, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...

Company Drug

Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case

Fineline Cube Apr 15, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...

Company Drug

Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe

Fineline Cube Apr 15, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...

Company Drug

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors

Fineline Cube Apr 15, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Deals

Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases

Fineline Cube Apr 15, 2025

Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....

Company Medical Device

Peijia Medical’s TaurusTrio TAV System Accepted for NMPA Review in China

Fineline Cube Apr 15, 2025

China-based Peijia Medical Ltd (HKG: 9996) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Apr 15, 2025

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...

Company Drug

Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259

Fineline Cube Apr 15, 2025

China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...

Company Deals

Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production

Fineline Cube Apr 15, 2025

Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured...

Company Deals

Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters

Fineline Cube Apr 15, 2025

UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)...

Company Drug

MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26

Fineline Cube Apr 14, 2025

US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...

Policy / Regulatory

NHC Urges Hospitals to Establish Healthy Weight Management Clinics by June

Fineline Cube Apr 14, 2025

The National Health Commission (NHC) has issued a notification encouraging eligible Class 3 general hospitals,...

Company Deals

Mabwell and DP Technology Collaborate to Build Biopharma AI Platform for Drug Development

Fineline Cube Apr 14, 2025

Chinese companies Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) and DP Technology have entered into...

Company Drug

Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment

Fineline Cube Apr 14, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...

Company Deals

Jiangxi Institute of Biological Products Files for Hong Kong IPO Amid Strong Market Position

Fineline Cube Apr 14, 2025

Jiangxi Institute of Biological Products Inc., China’s largest provider and exporter of human tetanus antitoxin...

Company Deals Drug

Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment

Fineline Cube Apr 14, 2025

Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of SYH2046 in Heart Failure

Fineline Cube Apr 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer

Fineline Cube Apr 14, 2025

US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...

Posts pagination

1 … 230 231 232 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.